Standing Out in the Crowd - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Standing Out in the Crowd
Supplier differentiation is increasingly important in the highly competitive arena of pharmaceutical outsourcing.


Pharmaceutical Technology
Volume 35, pp. s6

Amidst these conditions, we explore how contract-service providers can achieve competitive advantage by looking at the drivers that influence customers' perceptions of contract-service providers overall and in certain segments (see "Customer Drivers Influencing Supplier Differentiation").

As the level and complexity of outsourcing increases, bio/pharmaceutical companies speak about how project management is a valued competency of a contract-service provider not only in meeting its obligations, but also in working with other service providers. To illustrate, we offer a case study of a cross-functional supplier integration model (see "Achieving Cross-Functional Supplier Integration: A Case-Study Analysis").

Part of the task in developing a sustainable competitive advantage is to understand not only what customers value now, but what they will in the future. As bio/pharmaceutical companies begin to adapt quality by design (QbD) in their drug-development and manufacturing efforts, will competency in QbD become equally important for contract-service providers? We gain perspectives from both sides of this issue. Senior executives from Pfizer offer insight on the company's experience with QbD (see "A Pharma Manufacturer’s View of Quality by Design"), and an industry roundtable of technology and contract-service providers share their views on the influence of QbD on the outsourced relationship (see "Evaluating QbD's Impact on the Outsourced Relationship").

Also in this issue, Avantor shares its experience in a pilot of the shared audit process of Rx–360, the international pharmaceutical supply-chain consortium (see "Rx-360 Completes Pilot Audit of Manufacturing Facility: An Industry Case Study from Avantor"). We also share best practices in collaborative planning (see "Outsourced Manufacturing Operations") and technology transfer (see "Managing Technology Transfer: Developing a Complete CMC Package for an In-Licensed Product").

Patricia Van Anrum is a senior editor of Pharmaceutical Technology,
and a co-editor of this special issue.

References

1. M.E. Porter, Competitive Advantage: Creating and Sustaining Superior Performance (Free Press, 1st ed., New York, 1985).

2. M.E. Porter, Competitive Strategy: Techniques for Analyzing Industries and Competitors (Free Press, 1st ed., New York, 1980).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here